Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF
Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
NU22-03-00136
Ministerstvo Zdravotnictví Ceské Republiky (Ministry of Health of the Czech Republic)
PubMed
38472478
PubMed Central
PMC10997522
DOI
10.1038/s41375-024-02215-9
PII: 10.1038/s41375-024-02215-9
Knihovny.cz E-zdroje
- MeSH
- chronická myeloidní leukemie * farmakoterapie MeSH
- chronická nemoc MeSH
- inhibitory proteinkinas terapeutické užití MeSH
- inhibitory tyrosinkinasy MeSH
- lidé MeSH
- myeloidní leukemie * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Česká republika MeSH
- Názvy látek
- inhibitory proteinkinas MeSH
- inhibitory tyrosinkinasy MeSH
1st Dpt of Internal Medicine Hematology General University Hospital Prague Czech Republic
Central European Institute of Technology Masaryk University Brno Czech Republic
Department of Pharmacology Faculty of Medicine Masaryk University Brno Czech Republic
Dpt of Hemato oncology University Hospital Olomouc and Palacký University Olomouc Czech Republic
Dpt of Hemato oncology University Hospital Ostrava and Ostrava University Ostrava Czech Republic
Dpt of Hemato oncology University Hospital Plzeň and Charles University Plzeň Czech Republic
Institute of Hematology and Blood Transfusion Prague Czech Republic
Zobrazit více v PubMed
Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966–84. doi: 10.1038/s41375-020-0776-2. PubMed DOI PMC
Sharf G, Marin C, Bradley JA, Pemberton-Whiteley Z, Bombaci F, Christensen RIO, et al. Treatment-free remission in chronic myeloid leukemia: the patient perspective and areas of unmet needs. Leukemia. 2020;34:2102–12. doi: 10.1038/s41375-020-0867-0. PubMed DOI PMC
Sanford D, Kyle R, Lazo-Langner A, Xenocostas A, Chin-Yee I, Howson-Jan K, et al. Patient preferences for stopping tyrosine kinase inhibitors in chronic myeloid leukemia. Curr Oncol. 2014;21:e241–9. doi: 10.3747/co.21.1736. PubMed DOI PMC
Breccia M, Efficace F, Sica S, Abruzzese E, Cedrone M, Turri D, et al. Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients. Leuk Res. 2015;39:1055–9. doi: 10.1016/j.leukres.2015.07.004. PubMed DOI
Jiang Q, Liu ZC, Zhang SX, Gale RP. Young age and high cost are associated with future preference for stopping tyrosine kinase inhibitor therapy in Chinese with chronic myeloid leukemia. J Cancer Res Clin Oncol. 2016;142:1539–47. doi: 10.1007/s00432-016-2159-7. PubMed DOI PMC
Lou J, Huang J, Wang Z, Wen B, Tu C, Huang W, et al. Chronic myeloid leukemia patients and treatment-free remission attitudes: a multicenter survey. Patient Prefer Adherence. 2018;12:1025–32. doi: 10.2147/PPA.S163393. PubMed DOI PMC
Villemagne Sanchez LA, O’Callaghan C, Gough K, Hall K, Kashima Y, Seymour JF, et al. Patient perceptions of treatment-free remission in chronic myeloid leukemia. Leuk Lymphoma. 2018;59:406–15. doi: 10.1080/10428194.2017.1337114. PubMed DOI
Flynn KE, Myers JM, D’Souza A, Schiffer CA, Thompson JE, Atallah E. Exploring Patient Decision Making Regarding Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia. Oncologist. 2019;24:1253–8. doi: 10.1634/theoncologist.2018-0831. PubMed DOI PMC
Tromp VNMF, Timmers L, Koningen L, Janssen JJWM, Westerweel PE, Geelen IGP, et al. Tyrosine kinase inhibitor treatment discontinuation in chronic myeloid leukemia: patient views. Leuk Lymphoma. 2021;62:649–58. doi: 10.1080/10428194.2020.1839655. PubMed DOI
Chen Y, Xu N, Yang Y, Liu Z, Xue M, Meng L, et al. Quality-of-life, mental health, and perspective on TKI dose reduction as a prelude to discontinuation in chronic phase chronic myeloid leukemia. Cancer Med. 2023;12:17239–52. doi: 10.1002/cam4.6296. PubMed DOI PMC
Saglio G, Sharf G, Almeida A, Bogdanovic A, Bombaci F, Čugurović J, et al. Considerations for Treatment-free Remission in Patients With Chronic Myeloid Leukemia: A Joint Patient-Physician Perspective. Clin Lymphoma Myeloma Leuk. 2018;18:375–9. doi: 10.1016/j.clml.2018.04.005. PubMed DOI
Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19:747–57. doi: 10.1016/S1470-2045(18)30192-X. PubMed DOI
Berger MG, Pereira B, Rousselot P, Cony-Makhoul P, Gardembas M, Legros L, et al. Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome. Br J Haematol. 2019;187:337–46. doi: 10.1111/bjh.16083. PubMed DOI
Copland M. Is There a Role for Dose Modification of TKI Therapy in CML? Curr Hematol Malig Rep. 2019;14:337–45. doi: 10.1007/s11899-019-00524-w. PubMed DOI PMC
Clark RE, Polydoros F, Apperley JF, Milojkovic D, Rothwell K, Pocock C, et al. De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. Lancet Haematol. 2019;6:e375–83. doi: 10.1016/S2352-3026(19)30094-8. PubMed DOI
